MedTrace Logo

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

NCT03525652 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-05-16

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of a therapeutic vaccine in combination with PD-1 knockout T cells in the treatment of advanced prostate cancer.

Conditions

Interventions

BIOLOGICAL

Therapeutic vaccine

The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.

BIOLOGICAL

PD-1 Knockout T Cells

PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.

Sponsors & Collaborators

  • Guangzhou Anjie Biomedical Technology Co., Ltd.

    collaborator INDUSTRY

  • University of Technology, Sydney

    collaborator OTHER

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    lead OTHER

Principal Investigators

  • Size Chen, MD, PhD · The First Affiliated Hospital of Guangdong Pharmaceutical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-22
Primary Completion
2021-02-22
Completion
2021-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03525652 on ClinicalTrials.gov